Latest Research Reports

Acute Myeloid Leukemia: noticeable differences in subtypes by age

Acute Myeloid Leukemia: noticeable differences in subtypes by age

Bispecific antibodies and CAR-T cells: A comparison of historical trial numbers and patient recruitment

Bispecific antibodies and CAR-T cells: A comparison of historical trial numbers and patient recruitment

Long-term effects of GHD treatment in children unclear

Long-term effects of GHD treatment in children unclear

HER2 expression associated with poorer prognosis, but found more frequently in non-invasive breast cancer

HER2 expression associated with poorer prognosis, but found more frequently in non-invasive breast cancer

US Sees High Rates of Ovarian Cancer Diagnosed at Stage IV

US Sees High Rates of Ovarian Cancer Diagnosed at Stage IV

Type 2 Diabetes Leads Indications in Russian Clinical Trials, 2012-2016

Type 2 Diabetes Leads Indications in Russian Clinical Trials, 2012-2016

The need for action: improving awareness and early diagnosis of SLE

The need for action: improving awareness and early diagnosis of SLE

Urban China stands out from US, major European markets and Japan when comparing invasive breast cancer HER2 status

Urban China stands out from US, major European markets and Japan when comparing invasive breast cancer HER2 status

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

A large number of clinical trials evaluating inhibitors of the enzyme poly ADP ribose polymerase (PARP) in breast and ovarian cancers are either ongoing or completed....

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Targeted therapies will radically improve head and neck cancer treatment

Head and neck cancer (HNC) is the sixth most common cancer worldwide, and the majority of available treatments are highly toxic...

Targeted therapies will radically improve head and neck cancer treatment

Amgen and Cytokinetics: moving forward with chronic heart failure therapy

In December, Amgen and Cytokinetics announced that they will be moving forward with their novel chronic heart failure (HF) therapy omecamtiv mecarbil (OM) with the launch of their Phase III...

Amgen and Cytokinetics: moving forward with chronic heart failure therapy